Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Tax Provisions (2016 - 2025)

Cytosorbents' Tax Provisions history spans 15 years, with the latest figure at -$1000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at -$1000.0 for Q4 2025, up 99.94% from a year ago — trailing twelve months through Dec 2025 was -$2.1 million (up 16.44% YoY), and the annual figure for FY2025 was -$401000.0, up 76.29%.
  • Tax Provisions for Q4 2025 was -$1000.0 at Cytosorbents, up from -$401000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of -$1000.0 in Q4 2025 to a low of -$1.7 million in Q4 2024.
  • The 5-year median for Tax Provisions is -$774871.0 (2021), against an average of -$789221.2.
  • The sharpest move saw Tax Provisions plummeted 107.81% in 2024, then surged 99.94% in 2025.
  • Year by year, Tax Provisions stood at -$736003.0 in 2021, then crashed by 48.45% to -$1.1 million in 2022, then grew by 25.52% to -$813739.0 in 2023, then plummeted by 107.81% to -$1.7 million in 2024, then surged by 99.94% to -$1000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at -$1000.0, -$401000.0, and -$1.7 million for Q4 2025, Q3 2025, and Q4 2024 respectively.